Navigation Links
Gene Studies Could Point to New Alzheimer's Treatments
Date:4/25/2013

THURSDAY, April 25 (HealthDay News) -- Insight into genes that play a key role in disrupting immune system pathways in the brains of people with Alzheimer's disease could offer a potential target for new drugs against the disease, two new studies show.

"Defining the precise steps of the inflammatory response crucial to causing Alzheimer's disease has been elusive. We are pleased to discover these novel insights into that process," Bin Zhang, lead author of one of the studies and an associate professor of genetics and genomic sciences at the Icahn School of Medicine at Mount Sinai in New York City, said in a school news release.

In the study, Zhang's team analyzed brain tissue samples from deceased Alzheimer's patients, as well as healthy people who had died. By measuring the activity level of thousands of genes in these tissue samples, the team identified which gene networks are disrupted in diseased brains.

Specifically, their analysis pinpointed the important role of a gene expressed in immune cells called microglia, which clean up debris and destroy pathogens in the brain.

This gene, called TYROBP, is overactive in the brains of Alzheimer's patients and plays a major role in disrupting the activity of many other genes that control microglia activation, according to the study, which was published April 25 in the journal Cell.

"As a next step, we will evaluate drugs that impact [this] pathway as potential therapies for the disease," Zhang said. "This discovery enables us to design more specific compounds that target these key steps precisely, in contrast to existing anti-inflammatory drugs that may be less ideal for hitting this target."

Another study, published online April 25 in the journal Neuron, may have uncovered another genetic clue to Alzheimer's disease.

Researchers looked at brain samples from deceased Alzheimer's patients and found that higher activity of a gene called CD33 in microglia was linked to higher levels of the beta-amyloid protein plaques that have long been associated with Alzheimer's disease.

In their experiments with mice, switching off CD33 activity seemed to help microglia sweep away the plaques.

"Our findings suggest that pharmaceutical inactivation of CD33 represents a potentially powerful new therapy for the treatment and prevention of Alzheimer's disease, and perhaps other neurodegenerative disorders," senior study author Rudolph Tanzi, of Massachusetts General Hospital and Harvard Medical School in Boston, said in a journal news release.

Another expert said the findings from both studies may help advance research.

"We have known for a long time that Alzheimer's disease is characterized by the presence of excessive inflammation in the brain," said Philippe Marambaud, an investigator at the Litwin-Zucker Research Center for the Study of Alzheimer's Disease at the Feinstein Institute for Medical Research in Manhasset, N.Y.

"The role of this inflammatory response in the pathogenic mechanisms of the disease, however, remains unclear," he said. "These two studies ... provide concordant evidence that the immune cells microglia actively participate in this disease process."

More information

The U.S. National Institute of Neurological Disorders and Stroke has more about Alzheimer's disease.

-- Robert Preidt

SOURCES: Philippe Marambaud, Ph.D., investigator, Litwin-Zucker Research Center for the Study of Alzheimer's Disease, Feinstein Institute for Medical Research, Manhasset, N.Y.; Cell, news release, April 25, 2013; Neuron,news release, April 25, 2013; Icahn School of Medicine at Mount Sinai, New York City, news release, April 25, 2013


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. New studies prove lethal link between alcohol, weight
2. Experimental Drug for Hepatitis C Promising, Studies Show
3. New studies explore mangos potential health-affirming properties
4. Pancreatic Cancer Correlation to Type 2 Diabetes Drugs Januvia and Byetta, New Studies Find Possible Connection
5. 2 landmark studies report on success of using image-guided brachytherapy to treat cervical cancer
6. Hard Physical Labor May Boost Risk of Heart Disease, Stroke: Studies
7. Penn State to Offer Human Development and Family Studies Degree Online
8. WriteResult Selected for Irritable Bowel Syndrome Studies
9. New Studies further support the use of Vitamin B6 for Fat Loss
10. Complementary and alternative medicine studies take center stage at EuroHeart Care
11. GW researcher studies the dangerous effects of cocaine on HIV patients
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Gene Studies Could Point to New Alzheimer's Treatments
(Date:12/8/2016)... ... , ... STAT courier is pleased to announce that due to customer demand, ... expanding their presence in Dallas. One of the most exciting parts for STAT is ... the Dallas and Forth Worth market. STAT takes pride in treating their employees with ...
(Date:12/8/2016)... ... December 08, 2016 , ... Vida Health, the digital health ... led by Canvas Ventures . Other investors include Nokia Growth Partners (NGP) and ... to serve more consumers who are managing chronic conditions or simply want ...
(Date:12/8/2016)... ... December 08, 2016 , ... Peter Zipp Insurance, an ... around the greater Phoenix metropolitan region, is announcing a charity event to provide ... the Homeless Youth Connection is to promote community awareness of the ongoing needs ...
(Date:12/8/2016)... ... 08, 2016 , ... Bill Mull Agencies, a Wichita-based firm ... around central Kansas, is joining the Youth Horizons organization for a charity event ... in Wichita, Youth Horizons works to empower area children from unstable, troubled, or ...
(Date:12/7/2016)... ... , ... Kenall Manufacturing, a leader in sealed healthcare lighting for more than ... multi-function, sealed, LED luminaire that meets the needs of everyone in the patient room ... , A 2’ x 4’ model features four modes: reading, ambient, standard and ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... 8, 2016  Boehringer Ingelheim announced today that it ... (CEI). This is the ninth time that the company ... a Best Place to Work for LGBT Equality. Administered ... a national benchmarking report on corporate policies and practices ... transgender (LGBT) employees. "We are committed ...
(Date:12/8/2016)... , December 8, 2016 ... "Sugar-Based Excipients Market by Product (Actual Sugars, Sugar ... (Filler & Diluent, Tonicity Agents), Formulation (Oral, Topical, ... MarketsandMarkets, the market has witnessed healthy growth during ... at a CAGR of 4.3% between 2016 and ...
(Date:12/8/2016)... 2016 According to a new market research report ... Therapeutic (Pain, Insulin)), End Use (Sports, Fitness, RPM), Type (Smart watch, Patch), ... global market, in terms of value, is projected to reach 12.14 Billion ... 18.0% during the forecast period. Continue Reading ... ...
Breaking Medicine Technology: